Rhythm Pharmaceuticals RYTM
Rhythm Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations
$110.68+28.04%close on Nov. 4, 2026 · volume 5.4M · Yahoo Finance
Price, last 52 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 14, 2026 | David P. Meeker President and CEO, director | Sold 10b5-1 plan | 50,000 | $102.67 $101.75-$105.19 | $5.13 million |
| Aug. 31, 2026 | Hunter C. Smith Chief Financial Officer | Sold 10b5-1 plan | 62,774 | $105.46 $104.59-$106.20 | $6.62 million |
| Aug. 13, 2026 | Joseph Shulman Chief Technical Officer | Sold 10b5-1 plan | 5,079 | $119.75 | $608,210 |
| Aug. 13, 2026 | Alastair Garfield Chief Scientific Officer | Sold 10b5-1 plan | 7,763 | $117.57 $116.11-$119.17 | $912,703 |
| Aug. 13, 2026 | Jennifer Kayden Lee EVP, Head of North America | Sold 10b5-1 plan | 75,834 | $117.38 | $8.90 million |
| Aug. 12, 2026 | Yann Mazabraud EVP, Head of International | Sold 10b5-1 plan | 57,000 | $116.15 $111.80-$117.47 | $6.62 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 12 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedRhythm Pharmaceuticals Q3 2026 net product revenue rises to $92.1 million, beating $84.6 million consensus; GAAP EPS $(0.61) beats $(0.74) estimate